Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Deal With BI, Lilly Gets Late-Stage Diabetes Drugs

Executive Summary

Eli Lilly & Co., on the precipice of one of the steepest patent cliffs in the industry, announced a diabetes collaboration with Boehringer Ingehheim GmbH Jan. 11 that will recharge the company's diabetes pipeline but may leave investors longing for bigger M&A action.

You may also be interested in...

Boehringer’s Trajenta Enters China As DPP-4 Latecomer, But Playing Field Still Level

Boehringer Ingelheim’s first diabetes product, Trajenta, has been approved in China. It enters China as the fourth DPP-4, but it may not have far to catch up given the reimbursement landscape.

Bristol And AstraZeneca Make A Splash In Diabetes With Joint Purchase Of Amylin

Bristol-Myers’ and AstraZeneca’s deal to acquire Amylin Pharmaceuticals for $7 billion, announced June 29, reaffirms the partners’ commitment to the vast and growing type 2 diabetes market, even if the competition is intense and the companies’ five-year-old alliance got off to a rocky start.

J&J’s Canagliflozin Positive Phase III Data In The Limelight At ADA

Five Phase III trials presented at ADA show J&J’s canagliflozin improves glycemic control over existing treatments and could offer a weight loss benefit to diabetes patients; they are part of a nine-study package that J&J submitted to FDA for approval May 31.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts